PF-232798

DB14813InvestigationalSmall molecule

PF-232798 is under investigation in clinical trial NCT01140425 (Study To Evaluate The Effect Of A Multiple Oral Dose Of PF-00232798 On QT Intervals In Healthy Subjects).

Mechanism: Pharmacologically active on C-C chemokine receptor type 5
Curator reviewed
Formula / weight: C₂₉H₄₀FN₅O₂ · 509.67 g/mol (avg)
Also known as: PF-00232798
Code names: PF-232798

Resolves to

Compound

UNII63P7W7886UCAS849753-15-7ChEMBLCHEMBL1649931

Structure

InChIKeyQETUKYDWZIRTEI-QUMGSSFMSA-NSMILESCC(C)C(=O)N1CCC2=C(C1)N=C(C)N2[C@@H]1C[C@@H]2CC[C@H](C1)N2CC[C@H](NC(C)=O)C1=CC=CC(F)=C1

Targets

P51681CCR5

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with PF-232798, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account